Cargando…
Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
BACKGROUND: Although oncolytic virotherapy has shown substantial promises as a new treatment modality for many malignancies, further improvement on its therapeutic efficacy will likely bring more clinical benefits. One plausible way of enhancing the therapeutic effect of virotherapy is to enable it...
Autores principales: | Ravirala, Divya, Mistretta, Brandon, Gunaratne, Preethi H, Pei, Guangsheng, Zhao, Zhongming, Zhang, Xiaoliu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261877/ https://www.ncbi.nlm.nih.gov/pubmed/34230110 http://dx.doi.org/10.1136/jitc-2021-002454 |
Ejemplares similares
-
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022) -
Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
por: Morales-Molina, Alvaro, et al.
Publicado: (2021) -
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
por: Hoang, Huy-Dung, et al.
Publicado: (2023) -
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
por: Nelson, Adam, et al.
Publicado: (2022) -
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)